Author: Chi Heem Wong; Kien Wei Siah; Andrew W Lo
Title: Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics Document date: 2020_4_14
ID: fnrm6a79_13
Snippet: We plot the number of development programs known to start in each month from January 2000 through December 2019 in Figure 1 . There are 1,838 and 706 industrysponsored and non-industry-sponsored vaccine development programs, respectively, and, 3,851 and 2,978 industry-sponsored and non-industry-sponsored non-vaccine drug development programs targeting infectious diseases, respectively. As can be seen from Figure 1a , the number of industry-sponso.....
Document: We plot the number of development programs known to start in each month from January 2000 through December 2019 in Figure 1 . There are 1,838 and 706 industrysponsored and non-industry-sponsored vaccine development programs, respectively, and, 3,851 and 2,978 industry-sponsored and non-industry-sponsored non-vaccine drug development programs targeting infectious diseases, respectively. As can be seen from Figure 1a , the number of industry-sponsored clinical programs attempting to treat infectious diseases is often greater than the number of vaccine development programs. The gap between the number of programs initiated for each development type seems to have increased between January 2000 and May 2014 before declining (see Section A7 for a more detailed analysis). We see a precipitous fall in the number of infectious disease treatment development programs initiated between late 2018 and mid-2019, which is likely to be related to declining investment in the research and development (R&D) of novel antibiotics, 8 Apr 2020 © 2020 by Wong, Siah, and Lo Page 4 of 25 All Rights Reserved precipitated by the closure of antibiotics biotechnology firms and the withdrawal of pharmaceutical companies from the antibiotics business (Hu, 2018; Langreth, 2019) .
Search related documents:
Co phrase search for related documents- drug development and infectious disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- drug development and infectious disease treat: 1
- drug development and non industry: 1, 2, 3, 4, 5, 6, 7, 8
- drug development and novel antibiotic: 1, 2, 3
- drug development and pharmaceutical company: 1, 2, 3
- drug development and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75
- drug development and vaccine development program: 1, 2, 3
- drug development program and infectious disease: 1, 2, 3
- infectious disease and month start: 1
- infectious disease and non industry: 1, 2, 3, 4, 5, 6
- infectious disease and novel antibiotic: 1, 2
- infectious disease and program number: 1
- infectious disease and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
- infectious disease and vaccine development program: 1, 2, 3
- infectious disease treat and non industry: 1
- infectious disease treat and vaccine development: 1
- non industry and pharmaceutical company: 1
- non industry and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- non industry and vaccine development program: 1
Co phrase search for related documents, hyperlinks ordered by date